Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  4SC AG    VSC   DE000A14KL72

4SC AG

(VSC)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/27/2019 | 01:35am EST

DGAP-News: 4SC AG / Key word(s): Conference
4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens

27.09.2019 / 07:30
The issuer is solely responsible for the content of this announcement.


Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens

  • More than 140 patients enrolled
  • Top-line results expected towards the middle of 2020

Planegg-Martinsried, Germany, 27 September 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced that Prof. R. Stadlerof University Hospital of Dermatology, Minden, Germany will provide an update on the ongoing pivotal RESMAIN study at the EORTC Cutaneous Lymphoma Task Force Meeting in Athens, 26-28 September 2019.

RESMAIN is conducted as a multi-center, double blind, randomized, placebo-controlled study. It evaluates resminostat for maintenance treatment of patients with advanced-stage cutaneous T-cell lymphoma (CTCL) who have achieved disease control with prior systemic therapy, at more than 50 clinical centers in 11 European countries and Japan. The study is progressing well and top-line results are expected towards the middle of 2020.

- Press release ends -

 

Related articles

28 January 2019, 4SC's pivotal RESMAIN study of resminostat in CTCL receives second positive safety review

20 November 2018, 4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintenance therapy

28 June 2018, New data supports resminostat's mechanism of action in CTCL maintenance therapy

27 March 2018, Yakult Honsha joins 4SC's pivotal RESMAIN study of resminostat in CTCL - 4SC receives milestone payment

Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 June 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

About resminostat

Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. Resminostat demonstrated that it is well tolerated and can inhibit tumor growth and proliferation, cause tumor regression, and strengthen the body's immune response to cancer.

Resminostat has been shown to be well tolerated in several clinical trials. Resminostat is currently being investigated in a pivotal study in cutaneous T-cell lymphoma (CTCL) by 4SC and a Phase II study in biliary tract cancer by 4SC's development partner Yakult Honsha in Japan.

About cutaneous T-cell lymphoma (CTCL)

CTCL is a rare disease with approximately 5,000 patients being newly diagnosed in Europe each year. The disease arises from malignant transformation of T cells, a specialized subgroup of immune cells, primarily affects the skin, but may ultimately involve lymph nodes, blood and visceral organs.

Currently, CTCL is not curable and treatment options for advanced-stage CTCL are limited. Although patients respond to the available treatment options, the duration of response is often short-lived and declines as the severity of the disease increases. The key therapeutic challenge in advanced-stage CTCL is therefore to make remissions more durable, halting disease progression, improving quality of life and prolonging progression free and overall survival.

About the RESMAIN study - Resminostat for maintenance treatment of CTCL

The pivotal RESMAIN study is being conducted at more than 50 clinical centers in 11 European countries and Japan. It will include up to 190 patients who suffer from advanced-stage cutaneous T-cell lymphoma (CTCL) and have achieved disease control with systemic therapy. The patients are randomized 1:1 to receive either resminostat or placebo. Patients who experience disease progression - while being on placebo - will be offered resminostat in an open label treatment arm.

The primary goal of the study is to determine whether maintenance treatment with resminostat prolongs progression-free survival and the key secondary objective is to prolong the time to symptom worsening (itching). A comprehensive biomarker program is also included in the study to ensure vital knowledge about the biological background of resminostat treatment and CTCL is acquired. 4SC anticipates top-line data to be available in 2020.

The concept of maintenance therapy

The pivotal RESMAIN study is focused on patients with advanced-stage, incurable cutaneous T-cell lymphoma CTCL. Such patients suffer from painful and itchy skin lesions resulting in disfigurement and a severely impaired quality of life. Furthermore, lymph nodes, blood or visceral organ can be involved. None of the current therapeutic options achieve stable disease for long periods, with most patients progressing within six months on average.

Resminostat is being evaluated as maintenance treatment - prolonging the period patients are stable and not progressing. Recent preclinical data further suggests that resminostat has the potential to alleviate the itching in CTCL patients, thereby additionally improving the quality of life for patients.

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

 

Contact

ir-pr@4sc.com
+49 89 700763-0



27.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
Phone: +49 89 700763-0
Fax: +49 89 700763-29
E-mail: ir-pr@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 880505

 
End of News DGAP News Service

880505  27.09.2019 

fncls.ssp?fn=show_t_gif&application_id=880505&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on 4SC AG
11/204SC AG : Correction of a release from 19/11/2019 according to Article 40, Sectio..
EQ
11/194SC AG : Release according to Article 40, Section 1 of the WpHG [the German Secu..
EQ
11/144SC AG : Release according to Article 41 of the WpHG [the German Securities Trad..
EQ
11/124SC : secures circa EUR 22.4 million from a capital increase
EQ
10/214SC AG : Poster presentation at 1st International Symposium on Merkel Cell Carci..
EQ
10/174SC : provides Q3 business update and outlook
EQ
10/164SC : and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Dom..
EQ
10/104SC AG : Conference call to be hosted on 17 October 2019 to present the Q3 Annou..
EQ
10/074SC : resolves to issue new shares; Santo and ATS undertake to subscribe / buy t..
EQ
09/304SC AG : First domatinostat combination data from Phase Ib/II SENSITIZE study pr..
EQ
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 108 M
Chart 4SC AG
Duration : Period :
4SC AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 2,36  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Jason Loveridge Chief Executive Officer
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Manfred Rüdiger Member-Supervisory Board
Helmut Jeggle Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG-19.61%110
IQVIA HOLDINGS INC.25.12%28 203
LONZA GROUP32.23%25 328
INCYTE CORPORATION47.81%20 245
SEATTLE GENETICS, INC.106.78%20 080
CELLTRION, INC.--.--%18 090